Luspatercept 25 mg, 75 mg Suppliers & Bulk Manufacturers

Luspatercept is used to treat anaemia in adults with beta-thalassemia who require regular red blood cell transfusions. It is also used in certain patients with myelodysplastic syndromes (MDS) to reduce the need for blood transfusions.

It is made from a recombinant fusion protein that binds to specific TGF-beta superfamily ligands, helping enhance late-stage red blood cell maturation in the bone marrow.

The trade name is Reblozyl.

Luspatercept (Reblozyl) is manufactured by Bristol Myers Squibb in collaboration with Acceleron Pharma.

The generic name is Luspatercept-aamt.

The brand name is Reblozyl.

It is manufactured in the United States and other approved Bristol Myers Squibb production sites globally.

1 mg/kg under the skin every 3 weeks, increased to 1.33 mg/kg and then 1.75 mg/kg if transfusion needs do not fall.

Adults with transfusion-dependent beta-thalassaemia and those with anaemia from lower-risk myelodysplastic syndromes, including those with ring sideroblasts.

As lyophilised powder at 2–8 °C, reconstituted with water for injection just before use.

Reblozyl (Luspatercept) is developed and sold by Bristol Myers Squibb. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.